SOCS2-AS1 has recently been validated as a tumor suppressor in colorectal and endometrial cancers, and its low expression in tumors was positively related to poor prognosis of patients (Zheng et al., 2020; Jian et al., 2021). This evidence concerns the gene SOCS2 and neoplasm.